Cargando…

Distinctive mutational spectrum and karyotype disruption in long-term cisplatin-treated urothelial carcinoma cell lines

The DNA-damaging compound cisplatin is broadly employed for cancer chemotherapy. The mutagenic effects of cisplatin on cancer cell genomes are poorly studied and might even contribute to drug resistance. We have therefore analyzed mutations and chromosomal alterations in four cisplatin-resistant bla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Skowron, Margaretha A., Petzsch, Patrick, Hardt, Karin, Wagner, Nicholas, Beier, Manfred, Stepanow, Stefanie, Drechsler, Matthias, Rieder, Harald, Köhrer, Karl, Niegisch, Günter, Hoffmann, Michèle J., Schulz, Wolfgang A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785536/ https://www.ncbi.nlm.nih.gov/pubmed/31597922 http://dx.doi.org/10.1038/s41598-019-50891-w

Ejemplares similares

The New Immortalized Uroepithelial Cell Line HBLAK Contains Defined Genetic Aberrations Typical of Early Stage Urothelial Tumors
por: Hoffmann, Michèle J., et al.
Publicado: (2016)

Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells
por: Höhn, Annika, et al.
Publicado: (2016)

Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines
por: Skowron, Margaretha A., et al.
Publicado: (2018)

Combination of Decitabine and Entinostat Synergistically Inhibits Urothelial Bladder Cancer Cells via Activation of FoxO1
por: Wang, Chenyin, et al.
Publicado: (2020)

Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines
por: Skowron, Margaretha A., et al.
Publicado: (2017)

Proteomic and transcriptomic profiles of human urothelial cancer cells with histone deacetylase 5 overexpression
por: Jaguva Vasudevan, Ananda Ayyappan, et al.
Publicado: (2022)

Knockdown of UTX/KDM6A Enriches Precursor Cell Populations in Urothelial Cell Cultures and Cell Lines
por: Lang, Alexander, et al.
Publicado: (2020)

Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines
por: Skowron, Margaretha A., et al.
Publicado: (2015)

Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment
por: Berning, Lena, et al.
Publicado: (2021)

HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition
por: Jaguva Vasudevan, Ananda Ayyappan, et al.
Publicado: (2019)

Epigenetic Treatment of Urothelial Carcinoma Cells Sensitizes to Cisplatin Chemotherapy and PARP Inhibitor Treatment
por: Thy, Sophia, et al.
Publicado: (2021)

Canonical Notch signalling is inactive in urothelial carcinoma
por: Greife, Annemarie, et al.
Publicado: (2014)

Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines
por: Hölscher, Alexander S., et al.
Publicado: (2018)

Contingencies of UTX/KDM6A Action in Urothelial Carcinoma
por: Lang, Alexander, et al.
Publicado: (2019)

Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines
por: Pinkerneil, Maria, et al.
Publicado: (2016)

Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment
por: Lehmann, Maria, et al.
Publicado: (2014)

Diagnostic and prognostic value of long noncoding RNAs as biomarkers in urothelial carcinoma
por: Droop, Johanna, et al.
Publicado: (2017)

Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?
por: Niegisch, Günter
Publicado: (2019)

HERV-K and LINE-1 DNA Methylation and Reexpression in Urothelial Carcinoma
por: Kreimer, Ulrike, et al.
Publicado: (2013)

Establishment and Evaluation of Dual HDAC/BET Inhibitors as Therapeutic Options for Germ Cell Tumors and Other Urological Malignancies
por: Burmeister, Aaron, et al.
Publicado: (2022)

Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine
por: Isono, Makoto, et al.
Publicado: (2017)

Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells
por: Grunewald, Camilla M., et al.
Publicado: (2021)

Therapeutical interference with the epigenetic landscape of germ cell tumors: a comparative drug study and new mechanistical insights
por: Müller, Melanie R., et al.
Publicado: (2022)

Multiple Mechanisms Mediate Resistance to Sorafenib in Urothelial Cancer
por: Knievel, Judith, et al.
Publicado: (2014)

CDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms
por: Skowron, Margaretha A., et al.
Publicado: (2020)

Many Different LINE-1 Retroelements Are Activated in Bladder Cancer
por: Whongsiri, Patcharawalai, et al.
Publicado: (2020)

Concomitant downregulation of the imprinted genes DLK1 and MEG3 at 14q32.2 by epigenetic mechanisms in urothelial carcinoma
por: Greife, Annemarie, et al.
Publicado: (2014)

The long noncoding RNA HOTAIR has tissue and cell type-dependent effects on HOX gene expression and phenotype of urothelial cancer cells
por: Heubach, Judith, et al.
Publicado: (2015)

Effects of novel HDAC inhibitors on urothelial carcinoma cells
por: Kaletsch, Aline, et al.
Publicado: (2018)

Genome sequencing of Chlamydia trachomatis serovars E and F reveals substantial genetic variation
por: Eder, Thomas, et al.
Publicado: (2017)

The transcription factor reservoir and chromatin landscape in activated plasmacytoid dendritic cells
por: Mann-Nüttel, Ritu, et al.
Publicado: (2021)

Basic Hallmarks of Urothelial Cancer Unleashed in Primary Uroepithelium by Interference with the Epigenetic Master Regulator ODC1
por: Erichsen, Lars, et al.
Publicado: (2020)

Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells
por: Hoffmann, Michèle J., et al.
Publicado: (2021)

Response of the Urothelial Carcinoma Cell Lines to Cisplatin
por: Holíčková, Andrea, et al.
Publicado: (2022)

Tumorigenic effects of human mesenchymal stromal cells and fibroblasts on bladder cancer cells
por: Frerichs, Lucie M., et al.
Publicado: (2023)

Insulin-Like Growth Factor 1 Attenuates the Pro-Inflammatory Phenotype of Neutrophils in Myocardial Infarction
por: Nederlof, Rianne, et al.
Publicado: (2022)

Does robotic radical cystectomy impede oncological outcome in bladder cancer patients?
por: Niegisch, Günter
Publicado: (2018)

Distinct mechanism of formation of the 48, XXYY karyotype
por: Balsera, Aránzazu Margallo, et al.
Publicado: (2013)

Truncated Isoforms of lncRNA ANRIL Are Overexpressed in Bladder Cancer, But Do Not Contribute to Repression of INK4 Tumor Suppressors
por: Hoffmann, Michèle J., et al.
Publicado: (2015)

Alterations of Chromatin Regulators in the Pathogenesis of Urinary Bladder Urothelial Carcinoma
por: Hoffmann, Michèle J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tqd4ahsjba218eraicbunedi69